Please note: The information displayed on this page might be outdated.
Advicenne: Advicenne is a specialty pharmaceutical company dedicated to patients suffering from rare and neglected diseases. The company's lead drug candidate, ADV7103, is currently pending European marketing authorization for distal renal tubular acidosis (dRTA), a kidney condition that can lead to severe complications. Advicenne is committed to developing and commercializing medications that are adapted to both children and adults because pathbreaking treatments for rare diseases should be available to patients of all ages.
Based in...
Europe, Public
Market Cap
2, rue Briçonnet
Nîmes, 30 000

Company Participants at European Biotech Investor Day 2019

  • Julie Rachline
  • Luc-Andre Granier, M.D., PhD, CEO & Medical Director

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Advicenne SA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Keren Finance SAS 1.32 106,637 0.83 Funds 2019-12-31
Ostrum Asset Management SA 1.29 103,967 0.81 Funds 2020-02-28
Amundi Asset Management SA (Investment Management) 0.69 55,873 0.43 Funds 2020-05-29
Etoile Gestion SA 0.64 51,400 0.40 Funds 2020-05-29
Gestys SA 0.16 13,000 0.10 Funds 2020-05-29
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.